AR049553A1 - Procesos para preparar compuestos e intermediarios quinolin-2-onas 8- sustituidas - Google Patents
Procesos para preparar compuestos e intermediarios quinolin-2-onas 8- sustituidasInfo
- Publication number
- AR049553A1 AR049553A1 ARP050102511A ARP050102511A AR049553A1 AR 049553 A1 AR049553 A1 AR 049553A1 AR P050102511 A ARP050102511 A AR P050102511A AR P050102511 A ARP050102511 A AR P050102511A AR 049553 A1 AR049553 A1 AR 049553A1
- Authority
- AR
- Argentina
- Prior art keywords
- quinolin
- oxy
- substituted
- aliphatic
- onas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a que dichos compuestos e intermediarios son utiles para tratar el asma y la enfermedad pulmonar obstructiva cronica (COPD). Reivindicacion 1: Un proceso para la preparacion de oxi-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin- 2-onas 8-sustituidas, o solvatos aceptables de las mismas, el cual comprende hacer reaccionar una oxi-(1H)-quinolin-2-ona 5-(alfa-haloacetil)-8-sustituida, con un agente reductor, en la presencia de un agente quiral y una base, para formar una 8- (oxi-sustituida)-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-ona, teniendo este agente quiral la formula (1) o (2), en donde: M es Ru, Rh, lr, Fe, Co, o Ni; L es arilo C6-24, o un residuo ariloC6-24-alifáticoC1-10, estando en cualquier caso opcionalmente enlazado con un polímero; X es hidrogeno o halogeno; R1 es un residuo alifático C1-10, cicloalifático C3-10, cicloalifáticoC3-10-alifáticoC1-10, ariloC6-24-alifáticoC1-10, o un grupo heterocíclico de 4 a 12 miembros que, en cada caso, está opcionalmente enlazado con un polímero; y R2 y R3 son fenilo; o R2 y R3, junto con el átomo de carbono con el que están unidos, forman un anillo de ciclohexano o ciclopentano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413960.6A GB0413960D0 (en) | 2004-06-22 | 2004-06-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049553A1 true AR049553A1 (es) | 2006-08-16 |
Family
ID=32799952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102511A AR049553A1 (es) | 2004-06-22 | 2005-06-17 | Procesos para preparar compuestos e intermediarios quinolin-2-onas 8- sustituidas |
| ARP110103340A AR082981A2 (es) | 2004-06-22 | 2011-09-14 | Proceso para la preparacion de sales de 5-[(r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103340A AR082981A2 (es) | 2004-06-22 | 2011-09-14 | Proceso para la preparacion de sales de 5-[(r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20090054653A1 (es) |
| EP (1) | EP1791820B1 (es) |
| JP (1) | JP5064214B2 (es) |
| KR (1) | KR101179302B1 (es) |
| CN (1) | CN1968927B (es) |
| AR (2) | AR049553A1 (es) |
| AT (1) | ATE450512T1 (es) |
| AU (1) | AU2005254698B2 (es) |
| BR (1) | BRPI0512298A (es) |
| CA (1) | CA2566388C (es) |
| CY (1) | CY1109884T1 (es) |
| DE (1) | DE602005018076D1 (es) |
| DK (1) | DK1791820T3 (es) |
| EC (1) | ECSP067100A (es) |
| ES (1) | ES2337273T3 (es) |
| GB (1) | GB0413960D0 (es) |
| HK (1) | HK1105121A1 (es) |
| HR (1) | HRP20100087T1 (es) |
| IL (1) | IL179600A (es) |
| MA (1) | MA28687B1 (es) |
| MX (1) | MXPA06014695A (es) |
| MY (1) | MY142051A (es) |
| NO (1) | NO339079B1 (es) |
| NZ (1) | NZ551276A (es) |
| PE (1) | PE20060304A1 (es) |
| PL (1) | PL1791820T3 (es) |
| PT (1) | PT1791820E (es) |
| RU (1) | RU2383534C2 (es) |
| SI (1) | SI1791820T1 (es) |
| TN (1) | TNSN06408A1 (es) |
| TW (1) | TWI347317B (es) |
| WO (1) | WO2005123684A2 (es) |
| ZA (1) | ZA200609257B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2044025T1 (sl) | 2006-06-30 | 2013-01-31 | Novartis Ag | Kinolinonski derivati in njihovi farmacevtski sestavki |
| EP1914227A1 (en) * | 2006-08-31 | 2008-04-23 | Novartis AG | Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist |
| US8877930B2 (en) | 2009-11-04 | 2014-11-04 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| US8680303B2 (en) | 2010-03-01 | 2014-03-25 | Massachusetts Institute Of Technology | Epoxidation catalysts |
| US8754085B2 (en) | 2010-07-14 | 2014-06-17 | Novartis Ag | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| CN104169282B (zh) | 2012-01-13 | 2016-04-20 | 诺华股份有限公司 | Ip受体激动剂的盐 |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| CN104053659B (zh) | 2012-01-13 | 2016-11-09 | 诺华股份有限公司 | 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类 |
| US20140357641A1 (en) | 2012-01-13 | 2014-12-04 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| CN104379566B (zh) * | 2012-07-11 | 2016-08-24 | 上海威智医药科技有限公司 | 茚达特罗中间体及茚达特罗的合成方法 |
| WO2014044288A1 (en) | 2012-09-21 | 2014-03-27 | Crystal Pharma Sa | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof |
| EP2897937B1 (en) | 2012-09-21 | 2017-12-06 | Crystal Pharma S.A.U | Process for the preparation of indacaterol and intermediates thereof |
| KR20150095888A (ko) | 2012-12-19 | 2015-08-21 | 노파르티스 아게 | 오토탁신 억제제 |
| JP2016507582A (ja) | 2013-02-13 | 2016-03-10 | ノバルティス アーゲー | Ｉｐ受容体アゴニスト複素環式化合物 |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| WO2014141069A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
| CZ306252B6 (cs) | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
| WO2014154841A1 (en) | 2013-03-27 | 2014-10-02 | Laboratorios Lesvi, S.L. | Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one |
| WO2015008229A1 (en) | 2013-07-18 | 2015-01-22 | Novartis Ag | Autotaxin inhibitors |
| JP6424219B2 (ja) | 2013-07-18 | 2018-11-14 | ノバルティス アーゲー | 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤 |
| WO2015104718A2 (en) | 2014-01-09 | 2015-07-16 | Davuluri, Ramamohan Rao | A novel process for preparation of indacaterol or its pharmaceutically acceptable salts |
| AU2015237857B2 (en) | 2014-03-27 | 2017-08-10 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| CN105693603B (zh) * | 2014-11-24 | 2019-11-29 | 上海医药工业研究院 | 改良的马来酸茚达特罗制备工艺 |
| KR101769204B1 (ko) * | 2015-08-04 | 2017-08-17 | 씨제이헬스케어 주식회사 | 크로마놀 유도체의 신규한 제조방법 |
| WO2017055506A1 (en) | 2015-09-29 | 2017-04-06 | Laboratorios Lesvi, S.L. | Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate |
| US10418663B2 (en) | 2016-05-17 | 2019-09-17 | Industrial Technology Research Institute | Metal-ion battery |
| CN107868045A (zh) * | 2016-09-28 | 2018-04-03 | 四川海思科制药有限公司 | 一种茚达特罗中间体的制备方法 |
| CN113731406B (zh) * | 2021-10-12 | 2023-07-28 | 南京工业大学 | 一种提高钯碳活性加氢脱除保护基的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| TWI324151B (en) * | 2003-04-02 | 2010-05-01 | Novartis Ag | Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones |
-
2004
- 2004-06-22 GB GBGB0413960.6A patent/GB0413960D0/en not_active Ceased
-
2005
- 2005-06-17 AR ARP050102511A patent/AR049553A1/es not_active Application Discontinuation
- 2005-06-20 PE PE2005000704A patent/PE20060304A1/es active IP Right Grant
- 2005-06-20 MY MYPI20052795A patent/MY142051A/en unknown
- 2005-06-21 WO PCT/EP2005/006686 patent/WO2005123684A2/en active Application Filing
- 2005-06-21 TW TW094120524A patent/TWI347317B/zh active
- 2005-06-21 EP EP05770221A patent/EP1791820B1/en active Active
- 2005-06-21 RU RU2007102228/04A patent/RU2383534C2/ru active
- 2005-06-21 AT AT05770221T patent/ATE450512T1/de active
- 2005-06-21 PT PT05770221T patent/PT1791820E/pt unknown
- 2005-06-21 PL PL05770221T patent/PL1791820T3/pl unknown
- 2005-06-21 US US11/569,140 patent/US20090054653A1/en not_active Abandoned
- 2005-06-21 CA CA2566388A patent/CA2566388C/en active Active
- 2005-06-21 NZ NZ551276A patent/NZ551276A/en unknown
- 2005-06-21 DE DE602005018076T patent/DE602005018076D1/de active Active
- 2005-06-21 SI SI200530921T patent/SI1791820T1/sl unknown
- 2005-06-21 ES ES05770221T patent/ES2337273T3/es active Active
- 2005-06-21 BR BRPI0512298-8A patent/BRPI0512298A/pt not_active Application Discontinuation
- 2005-06-21 JP JP2007517180A patent/JP5064214B2/ja active Active
- 2005-06-21 MX MXPA06014695A patent/MXPA06014695A/es active IP Right Grant
- 2005-06-21 AU AU2005254698A patent/AU2005254698B2/en active Active
- 2005-06-21 DK DK05770221.9T patent/DK1791820T3/da active
- 2005-06-21 KR KR1020067026958A patent/KR101179302B1/ko active IP Right Grant
- 2005-06-21 CN CN2005800195899A patent/CN1968927B/zh active Active
-
2006
- 2006-11-07 ZA ZA200609257A patent/ZA200609257B/en unknown
- 2006-11-27 IL IL179600A patent/IL179600A/en active IP Right Grant
- 2006-12-08 TN TNP2006000408A patent/TNSN06408A1/en unknown
- 2006-12-20 EC EC2006007100A patent/ECSP067100A/es unknown
- 2006-12-28 MA MA29571A patent/MA28687B1/fr unknown
-
2007
- 2007-01-22 NO NO20070400A patent/NO339079B1/no unknown
- 2007-09-25 HK HK07110434.6A patent/HK1105121A1/xx unknown
-
2010
- 2010-02-18 HR HR20100087T patent/HRP20100087T1/hr unknown
- 2010-03-01 CY CY20101100199T patent/CY1109884T1/el unknown
-
2011
- 2011-09-14 AR ARP110103340A patent/AR082981A2/es unknown
-
2012
- 2012-05-01 US US13/461,204 patent/US20120220775A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049553A1 (es) | Procesos para preparar compuestos e intermediarios quinolin-2-onas 8- sustituidas | |
| ATE439834T1 (de) | Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten | |
| TW200708513A (en) | Novel crystalline forms of tiotropium bromide | |
| DK1718336T3 (da) | Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme | |
| WO2006117300A3 (en) | Crystalline forms of tiotropium bromide | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| NO20081469L (no) | Fremgangsmåte for fremstilling, erstatning eller utvinning av gasshydrat | |
| DE60132828D1 (de) | Zusammensetzung enthaltend Formoterol und ein Glucocorticosteroid | |
| JP2010506950A5 (es) | ||
| AR047386A1 (es) | Uso de pteridinas sustituidas para el tratamiento de enfermedades de las vias respiratorias | |
| DK1734987T3 (da) | Interferon-beta til antivirusbehandling af respiratoriske sygdomme | |
| MX2009000999A (es) | Derivados de quinuclidina como antagonistas de m3. | |
| DE602005020661D1 (de) | Neuer schaumstoffmodifikator, aus diesem neuen schaumstoffmodifikator hergestellte schaumstoffe und verfahren zur herstellung dieser schaumstoffe | |
| CY1114636T1 (el) | Αγωγη συμπτωματων της νοσου του parkinson με αλκυλαμινες χωρις ιμιδαζολιο ως προσδετες η3-υποδοχεα ισταμινης | |
| ATE527507T1 (de) | Verfahren zur herstellung eines adsorberwärmetauschers | |
| UA111687C2 (uk) | Гетероароматичні сполуки як ліганди допаміну d1 | |
| AR072845A1 (es) | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. | |
| UY28596A1 (es) | Nuevo anhidrato cristalino con accion anticolinergica | |
| ATE451360T1 (de) | Halbsynthetisches verfahren zur herstellung von 10-desacetyl-n-desbenzoyl-paclitaxel | |
| SG179199A1 (en) | Phenyloxadiazole derivatives as pgds inhibitors | |
| EP1930872A3 (en) | Percussion instruments using molten or plasticized metal | |
| AR071734A1 (es) | Sintesis de compuestos de sales cuaternarias e intermediarios de la misma. | |
| DE502007000718D1 (de) | Verfahren zur Herstellung von Carbidkeramik-Bauteilen | |
| JP2006161114A5 (es) | ||
| TH94759A (th) | อนุพันธ์ควินูซลิดีนในฐานะเป็นตัวต้าน m3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |